Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
REGN(NASDAQ:REGN) TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025.
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
REGNCemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
REGNTARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics License Application (sBLA) seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications.
Regeneron Pharma Shares Rise Over 3% After Key Signal
REGNA significant trading signal occurred for Regeneron Pharma stock at a price of $501.83, after which REGN rose up to 3.2%.
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $800
REGNWatching Regeneron; At Goldman Sachs Conference, Exec Reportedly Says 23andMe Auction Process Was Recently Reopened And Is Fairly Complicated; Says Tariff Situation Currently Enacted Is Not Material To Business, But Sectoral Tariffs Could Have An Impact
REGNReported Saturday, Sanofi And Regeneron Present New Dupixent Results Highlighting Disease Severity Reduction In Patients With Darker Skin Tones
REGNUBS Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $560
REGNWhy Regeneron Is Falling And Why You Should Avoid It
REGNRegeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
REGNCitigroup Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $650
REGNBMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $600
REGNMorgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $755
REGNRegeneron Pharmaceutical Announced A Strategic In-licensing Agreement With Hansoh Pharmaceuticals Group Company Limited To Acquire Exclusive Clinical Development And Commercial Rights Outside Of The Chinese Mainland, Hong Kong And Macau For A Dual Glp-1/G
REGNReported Saturday, Regeneron's Libtayo Demonstrates Practice-Changing Results In Adjuvant High-Risk Cutaneous Squamous Cell Carcinoma With 87% Two-Year Disease-Free Survival
REGNForecasting The Future: 21 Analyst Projections For Regeneron Pharmaceuticals
REGNWells Fargo Downgrades Regeneron Pharmaceuticals to Equal-Weight, Lowers Price Target to $580
REGNRegeneron Pharmaceuticals Unusual Options Activity For May 30
REGNLooking Into Regeneron Pharmaceuticals's Recent Short Interest
REGNSanofi And Regeneron To Consult Regulators After Mixed Phase 3 COPD Results For Itepekimab, As AERIFY-1 Meets Primary Endpoint And AERIFY-2 Falls Short
REGNTelesis Bio Announces License Agreement With Regeneron Pharma To Deploy Telesis Bio's Revolutionary Gibson SOLA Platform At R&D Core Facilities
REGNRBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $943 Price Target
REGNHere's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
REGNRegeneron Pharmaceuticals Reveals Initial Results From Two Cohorts Of The Phase 1b LINKER-MM2 Trial Evaluating Linvoseltamab In Combination With Two Different Proteasome Inhibitors – Carfilzomib Or Bortezomib – In Patients With Relapsed/Refractory Multipl
REGNRegeneron Enters Asset Purchase Agreement To Acquire substantially All Assets Of 23andMe For $256M; Transaction Expected To Close In Q3
REGNRegeneron Pharma: Federal Court Jury Found Amgen Liable For Violating Antitrust And Tort Laws By Using Cross-Therapeutic Bundled Rebates To Prevent Praluent From Competing In Market; Jury Awarded Regeneron $135.6M Of Compensatory Damages And $271.2M In Pu
REGNBeyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock
REGNCitigroup Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $700
REGNPrice Over Earnings Overview: Regeneron Pharmaceuticals
REGNIf You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
REGNGuggenheim Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $810
REGNRegeneron Pharma To Present New And Updated Data From Oncology And Hematology Portfolio At ASCO Annual Meeting
REGNRegeneron Shares Are Up Today: What's Going On?
REGNShares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $940
REGNGoldman Sachs Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $804
REGNRBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $943
REGNWells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $700
REGNBMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $800
REGNUBS Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $633
REGNBaird Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $587
REGNRegeneron Pharma Margins Tighten As Competition Grows, Stock Slides
REGNRegeneron boosts antibody profits with higher Dupixent sales and expands biologics production via FUJIFILM Diosynth partnership.
Regeneron Pharmaceuticals Q1 Adj. EPS $8.22 Misses $8.82 Estimate, Sales $3.03B Miss $3.29B Estimate
REGNInsights into Regeneron Pharmaceuticals's Upcoming Earnings
REGNRegeneron Pharmaceuticals Announces The Upcoming Presentation Of 27 Abstracts, Including Eight Oral Presentations On EYLEA HD Injection 8 MG . Data Will Be Presented at the Association For Research In Vision and Ophthalmology 2025 Annual Meeting May 4 To
REGNRegeneron Pharmaceuticals Announces That The European Commission Has Granted Conditional Marketing Approval Of Lynozyfic To Treat Adults With Relapsed And Refractory Multiple Myeloma
REGNBaird Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $652
REGNTruist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $975
REGNRegeneron Expands US Manufacturing With $3 Billion Fujifilm Deal
REGNRegeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and long-term production.
Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $850
REGNCantor Fitzgerald Assumes Regeneron Pharmaceuticals at Overweight, Announces Price Target of $695
REGN